Progenics Pharmaceut (NASDAQ:PGNX)’s share price soared 0.69% or 0.06 to reach at $8.79 during previous trading session. A total of 1.01 Million shares exchanged hands, whereas the company’s average trading volume stands at 1.21 Million shares. Progenics Pharmaceut (NASDAQ:PGNX) has a market capitalization of $656.17 Million and most recently 74.65 Million outstanding shares have been calculated.

According to sentiments of 5 analysts the mean estimates of short term price target for the company’s stock is marked at $14.2. The most optimistic analyst sees the stock reaching $16 while the most conventional predicts the target price at $12.

In terms of Buy/Sell recommendations, 3 analysts have a consensus rating of 1 on the shares of Progenics Pharmaceut (NASDAQ:PGNX). Out of rating recommendations 3 have given the stock a Buy while 2 recommend the stock as Outperform. 0 have given the stock a Hold rating, 0 as Underperform and 0 as Sell.

Progenics Pharmaceut (NASDAQ:PGNX)’s shares climbed 5.27% in the past week and soared 18.46% in the last 4 weeks, historically the stock illustrate that its six months performance stands at 46.99% while its year to date performance is at 47.73%.

While taking a glance at financials, we can look at a number of key indicators. Progenics Pharmaceut (NASDAQ:PGNX) has a Return on Assets (ROA) of -31.5. The company currently has a Return on Equity (ROE) of -74.3 and a Return on Investment (ROI) of -44.6. Average true range (ATR-14) of the company sets at 0.29, along with its weekly and monthly volatility of 3.84% and 3.26% respectively. Relative strength index (RSI-14) for Progenics Pharmaceut (NASDAQ:PGNX) is at 75.99. Beta value of the stock stands at 2.67.

The company’s price to free cash flow for trailing twelve months is 0. Its quick ratio for most recent quarter is 6.4 along with current ratio for most recent quarter of 6.4. Total debt to equity ratio of Progenics Pharmaceut (NASDAQ:PGNX) for most recent quarter is 0.82 whereas long term debt to equity ratio for most recent quarter is 0.74.

Shares of Keryx Biopharm Inc (NASDAQ:KERX) soared 0.98% or 0.05 to reach at $5.17 during previous trading session. Keryx Biopharm Inc (NASDAQ:KERX) has a market capitalization of $634.05 Million and most recently 122.64 Million outstanding shares have been calculated. A total of 1.01 Million shares exchanged hands, whereas the company’s average trading volume stands at 1.11 Million shares.

According to 7 analysts Keryx Biopharm Inc (NASDAQ:KERX)’s price will reach at $6.79 during 52 weeks. Stock’s minimum price target estimates has been figured out at $5 while the maximum price target forecast is established at $9.

According to the recommendations from 6 analysts stock has mean rating of 2.17 on the shares of Keryx Biopharm Inc (NASDAQ:KERX). Out of rating recommendations 1 have given the stock a Buy while 3 recommend the stock as Outperform. 4 have given the stock a Hold rating, 0 as Underperform and 0 as Sell.

Shares of Keryx Biopharm Inc (NASDAQ:KERX) climbed 2.38% in the past week and plunged -1.52% in the last 4 weeks, historically the stock illustrate that its six months performance stands at 14.13% while its year to date performance is at 11.18%.

Total debt to equity ratio of Keryx Biopharm Inc (NASDAQ:KERX) for most recent quarter is 0 whereas long term debt to equity ratio for most recent quarter is 0. The company’s price to free cash flow for trailing twelve months is 0. Its quick ratio for most recent quarter is 1.9 along with current ratio for most recent quarter of 2.7.

Average true range (ATR-14) of the company sets at 0.26, along with its weekly and monthly volatility of 3.85% and 4.69% respectively. Relative strength index (RSI-14) for Keryx Biopharm Inc (NASDAQ:KERX) is at 50.61. Beta value of the stock stands at 2.6. Keryx Biopharm Inc (NASDAQ:KERX) has a Return on Assets (ROA) of -98.8. The company currently has a Return on Equity (ROE) of 0 and a Return on Investment (ROI) of -190.1.